Systematic review of traditional Chinese medicine Lianhua Qingwen in Seven studies reported the adverse reactions of hepatobiliary system damage. [9], During the COVID-19 pandemic, the government of the People's Republic of China (PRC) approved the use of Lianhua Qingwen for mild to moderate COVID-19 cases in January 2020, and promotes the use of the medicine abroad. Yiling Pharmaceutical (2020). doi:10.26434/chemrxiv.12016236.v1. As adverse reactions in COVID-19 pneumonia and chronic obstructive pulmonary disease treatment were only reported for a limited number of studies, no sensitivity analysis for these diseases was conducted. Traditional Chinese medicine formulation used for the treatment of influenza, Uses and controversies of Lianhua Qingwen in relation to COVID-19, by region, "How traditional Chinese medicine TCM is used to treat Covid-19", "The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule", "Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules", "Traditional Chinese cures battle for acceptance in COVID-19 fight", "Chinese traditional medicine for Covid-19 becomes money tree", "Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis", "Doctors warn against claims that Beijing-touted health supplement distributed in Canada treats COVID-19", "The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis", "Beijing pushes traditional Chinese medicine as coronavirus treatment", "China Covid-19 tsar pushed treatments without revealing business ties", "Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial", "Prominent Chinese scientist failed to disclose company ties in COVID-19 clinical trial paper", "DOH and FDA Clarify Claims on the Approval of Potential COVID-19 Treatments and Calls for Resignation of the SoH", "Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats symptoms, not COVID", "HSA Advisory on Lianhua Qingwen Products for Prevention or Treatment of COVID-19", "Fraudulent Coronavirus Disease 2019 (COVID-19) Products", "Chinese medicine Lianhua Qingwen makes its way into community for COVID-19 treatment despite Australian ban", https://en.wikipedia.org/w/index.php?title=Lianhua_Qingwen&oldid=1143380058, Short description is different from Wikidata, Articles needing expert attention from January 2023, Medicine articles needing expert attention, Articles containing simplified Chinese-language text, Articles containing traditional Chinese-language text, Articles with unsourced statements from August 2022, Creative Commons Attribution-ShareAlike License 3.0, Treatment against various respiratory diseases including, This page was last edited on 7 March 2023, at 11:01. In the evaluation of security indexes, our meta-analysis revealed that LHQW group having a lower level of adverse reactions compared to the conventional drug group, such as respiratory system damage, skin and its appendage damage, nervous system damage, gastrointestinal system damage and other adverse reactions. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. Business China. Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. Vahl. The following aspects were assessed for each study: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. A total of 420 participants with influenza (ages from 18 years to 65 years) were randomly divided into three groups: high dose LHQW capsule treatment (6 capsules each time, bid), low dose LHQW capsule treatment (4 capsules of LHQW+2 capsules of placebo each time, bid) and placebo intervention (6 capsules of placebo each time, bid). Besides, on April 14, 2020, the National Medical Products Administration of China approved modifying the specification of LHQW (Yiling Pharmaceutical Inc.) by adding a new indication for COVID-19 treatment in mild and normal cases. These results were different from our findings, which may be attributed to the limited number of adverse reactions reported in the previous study. Pharmacol. Till August 8, 2020, over 19,000,000 people have been confirmed infected and more than 700,000 people have died during this severe viral prevalence. Fig. In the evaluation of treating disease, significant reduced incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were detected in the LHQW group. Now, there are no study results posted on ClinicalTrials.gov for this study yet. To clarify the in vivo effects of LHQW, Gao and colleagues recently showed that LHQW could treat influenza A virus infection in H1N1 mouse model by improving pathologic alterations and body weight loss, and reducing virus replication, lung lesions as well as inflammation [19]. The documents were filtered and summarized for final evaluation. Meta-analysis in Clinical Trials. [citation needed]. Res. An official website of the United States government. Lianhua Qingwen - Wikipedia These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Therefore, people have also observed that Lianhua Qingwen capsule (granule) inhibits the over-expression of human common coronavirus (HcV-229E), novel coronavirus (COVID-19) infected cells and. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. The Plant List (2021). Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. [Caprifoliaceae; Lonicerae Japonicae Flos], Gypsum Fibrosum, Isatis indigotica Fort. Niu Q.Q., Chen Y., Liu Y., Mao S.Z., Wang H., Zheng W.K., Zhang J.H. The literature materials were collected from the scientific databases including the Pubmed, CNKI and Web of Science (up to August 8, 2020), on ethnobotany and ethno medicines. doi:10.1016/0197-2456(86)90046-2, Duval, S., and Tweedie, R. (2000). Efficacy and Safety of Lianhua Qingwen Granule Combined with Oseltamivir in the Treatment of Influenza Virus Infection in Children. Experiments on animals using a combination of LHQW and oseltamivir to treat influenza B virus infections showed a potential inhibitory effect on overexpression of TNF-, MIP-1, RANTES, IFN-, IL-6, IL-8, IP-10, and MCP-1 at the mRNA level, and consequent prevented of the development of severe inflammatory reactions (Yang et al., 2020). Royal Botanic Gardens, Kew science (2021). N. Engl. Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. The cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. This review has introduced the advances of LHQW in anti-viral treatment, intending to provide ideas for the timely treatment of COVID-19 patients. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. 37 studies reported adverse reactions of skin and its appendage damage. LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group (RR = 0.46, 95% CI = 0.290.74, p = 0.001). Therefore, it is essential to perform a systematic review and meta-analysis to assess the effect of Lianhua Qingwen combined with conventional antiviral Western Medicine in clinical treatment of COVID-19 or asymptomatic infection. Chin. Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Moher et al., 2009), and registered with PROSPERO (CRD42020224180). The LHQW group has a reduced incidence of gastrointestinal system damage than the conventional drug group (RR = 0.83, 95% CI = 0.740.93, p = 0.002). The current meta-analysis was conducted to systematically evaluate the security of LHQW compared with conventional drug in clinical application. Yao K.T., Liu M.Y., Li X., Huang J.H., Cai H.B. Am. The latest meta-analysis by Fan et al. Evid. An article on telemedicine and medical news platform Dr. Lilac pointed out that there was no scientific evidence available to indicate that LHQW was effective as prophylaxis to prevent infection, nor did there exist any official government recommendation for such usage; instead, taking the drug unnecessarily carried a risk of side effects. Clinical Practice Guideline on Treating Influenza in Adult Patients with Chinese Patent Medicines. Traditional Med. vahl (weeping forsythia) fruit 27.41 mg, Lonicera japonica Thunb. Efficacy of Lianhua Qingwen Compared with Conventional Drugs - Hindawi No proven effective antiviral treatments for COVID-19 pneumonia are available at present (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). Twelve representative compounds were further quantified as chemical markers, including amygdalin, forsythoside E, salidroside, glycyrrhizic acid, chlorogenic acid, hyperin, rutin, forsythoside A, cryptochlorogenic acid, sweroside, phillyrin, and rhein (Jia et al., 2015). Besides, the effective rate of chest CT in the LHQW group was 69.39 %, which was higher than 62.84 % in abidor group [44]. Both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing . Peng L.L., Li L., Shen L., Li X.L. Nervous system damage was described as an adverse event in 34 studies. J. Pharmacovigilance. The https:// ensures that you are connecting to the Are there any known contraindications? Results of publication bias and sensitivity analysis. (2015). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). A Trial of Lopinavir-Ritonavir in Covid-19. The basic clinical treatments for COVID-19 include anti-infectious, anti-proinflammatory cytokines, nonspecific antiviral as well as life support therapies [[6], [7], [8]]. Pharmacol. Publication bias data are shown in Table 2 and the Funnel plot of pooled studies presented in Figure 3. In addition to western medicine, the potential adverse drug reactions (ADRs) can not be ignored. Traditional Chinese medicine for pulmonary fibrosis therapy: progress and future prospects. First, the data indicated that LHQW combined with conventional therapies could markedly improve the clinical symptoms, quality of life and absorption of lung infiltration during anti-viral therapy, but the level of evidence is weak due to the included small sample trial and lacking the classification of disease severity. The current meta-analysis was performed to evaluate the safety profile of LHQW in relation to conventional drugs (PROSPERO CRD-42020224180). doi:10.1016/s1043661802002104, Hallas, J., Harvald, B., Gram, L. F., Grodum, E., Brsen, K., Haghfelt, T., et al. It has approved by China Food and Drug Administration (CFDA). LHQW prescription (capsules type, or granules type) consists of 11 herbs, gypsum and menthol [18]. Li J.Y., You Z., Wang Q., Zhou Z.J., Qiu Y., Luo R., Ge X.Y. Skin rashes, allergic dermatitis and other skin allergic reactions are also reported to be associated with LHQW treatment, and may be related to Houttuynia cordata Thunb. The sensitivity results are shown in Table 2. Front. Statistics showed that infected patients in China who received combined treatment of Traditional Chinese Medicine and modern medicine exhibited lower fatality rate and relatively better clinical outcomes. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. LHQW has been recommended by the China International Exchange and Promotive Association for Medical and Health Care and the Chinese Research Hospital Association as comprehensive treatment for moderate or chronic COVID-19 pneumonia in conjunction with routine therapy (Jin et al., 2020). Reply. Results: In total, 217 experimental studies were included. Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. Eval. Zhu S.Y., Li X.Y., Wei Y.L., Yang P.Y., Qin E.D. These in vivo data further demonstrate the antiviral effects of LHQW as well as its lung protection role. J. Eval. In treating fine particulates PM2.5 (7.5mg/kg)-exposed model rats, LHQW significantly relieved the pathological changes of thickened alveolar septum, congestion of capillary, interstitial edema and infiltration of lymphocyte and neutrophil surrounding bronchiole [34]. 339 (7), b2535. Electronic retrieval was performed using following databases, which were searched from outset to February 18, 2021: Embase, PubMed, the Cochrane Library, CNKI (a Chinese database), VIP (a Chinese database), and Wanfang (a Chinese database). Sci.). Cheng D.Z., Wang W.J., Li Y., Wu X.D., Zhou B., Song Q.Y. COPD is characterized by a chronic inflammatory response and can be worsened by acute exacerbations. 7 (3), 177188. The Chinese herbal medicine that can help treat COVID, according to doi:10.1111/jep.13614, Wang, Y. X., Zhang, K. Y., Huang, J. H., Han, S. L., Zhao, J. H., and Xu, Z. J. Zhang, R. X., and Liu, W. W. (2014). Efficacy and safety of Lianhuaqingwen for mild or moderate : Medicine Lianhua Qingwen capsule/granule (LHQW) is obtained by combining Ma Xing Shigan Decoction with Yinqiao Powder and widely used in the clinical treatment of respiratory disorders (Liu et al., 2010). (Yuxingcao), Pogostemon cablin (Blanco) Benth. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Some notable dangerous reactions include heart attacks, strokes, seizures, and sudden deaths. [16][17] A Filipino TCM physician interviewed by ABS-CBN clarified that although the medicine can be used for symptomatic treatment of flu-like symptoms in COVID-19 patients, it is not an antibiotic nor anti-viral, and cannot cure the disease itself. Wu, L., Chen, Y., Ma, Y., Yang, Z., Yang, N., Deng, W., et al. Subgroup, sensitivity and meta-regression analyses were conducted to determine the potential sources of heterogeneity. Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats System-Organ Code Retrieval Involved. doi:10.1016/j.jep.2013.12.022. Additionally, LHQW group also had shorter time to recovery of fever, fatigue and coughing, and higher improvement rate in chest computed tomographic manifestations and clinical cure [43]. Traditional Chin. doi:10.11954/ytctyy.201608076, Chan, K. W., Wong, V. T., and Tang, S. C. W. (2020). Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. A recent clinical trial including 36 common cold with wind-heat syndrome patients demonstrated that LHQW (three times daily for four days) treatment could significantly reduce TCM symptom score, with the median time to fever relief of (45) h and the median time to fever clearance of 36h [35]. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Qualitative and Quantitative Analysis of the Major Constituents in Chinese Medical Preparation Lianhua-Qingwen Capsule by UPLC-DAD-QTOF-MS. ScientificWorldJournal. LHQW was initially approved by the China Food and Drug Administration (CFDA) in 2004 and represents the first traditional Chinese medicine that passed the rapid drug approval channel of CFDA for treatment of severe acute respiratory syndrome (SARS). Nevertheless, pressing researches should be conducted to illuminate the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19. Before Four studies reported body as a whole-general disorders as an adverse event. Though the quality of the included literature was mixed, the lung protection effects of LHQW was demonstrated. National Library of Medicine 48 (3), 737762. The group reported significantly lower incidence of adverse reactions (RR = 0.62, 95% CI = 0.460.82) and lower incidence of gastrointestinal system damage in the LHQW group (RR = 0.65, 95% CI = 0.460.92) relative to the control group. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. A Working List of All Plant Species. Subgroup analysis additionally revealed a reduced incidence of some adverse reactions in the LHQW group compared to the conventional drug group (Rash of skin and its appendage damage, dizziness or headache owing to nervous system damage, nausea or vomiting from gastrointestinal system damage and resurgence of disease from other adverse reactions). Hsieh C.F., Lo C.W., Liu C.H., Lin S., Yen H.R., Lin T.Y., Horng J.T. Zhou X.P. Retrospective Clinical Analysis on Treatment of Novel Coronavirus-Infected Pneumonia with Traditional Chinese Medicine Lianhua Qingwen. 1: An overview of approach to pharmacokinetics-based identification of potential therapeutic compounds from LianhuaQingwen, a Chinese herbal used as treatment for COVID-19. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf (Accessed July 23, 2021). It includes Forsythia suspensa (Thunb.) CFDA has recently approved adding a new indication for LHQW in mild and common COVID-19 patients, but whether it would bring benefits for the severe cases is unclear. Res. As the Financial Times report showed, these appeared to be serious conflicts of interest as the investments benefited from the PRC and HK governments' rapid approval and then widespread national & international promotion of Lianhua Qingwen and other suspect treatments for purportedly helping COVID-19 sufferers. Ling X.Y., Tao J.L., Sun X., Yuan B. In addition, LHQW treatment efficiently impaired the nuclear export of the viral RNPl [24]. Jia W., Wang C., Wang Y., Pan G., Jiang M., Li Z., Zhu Y. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS. Wang C.H., Zhong Y., Zhang Y., Liu J.P., Wang Y.F., Jia W.N., Wang G.C., Li Z., Zhu Y., Gao X.M. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Lianhua Qingwen Dosage & Drug Information | MIMS Philippines Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. These in vitro studies indicate that LHQW shows a wide range of antiviral activities including its anti-SARS-CoV-2 role. Recently, a single center retrospective study showed that LHQW granules (6g, tid) combined with conventional therapy (nutritional support therapy, symptomatic therapy, antiviral and antibiotic medication) could significantly relieve the symptoms like fever, cough, weakness and short breath in COVID-19 suspected cases with good safety [40]. Lianhua Qingwen has antiviral, anti-inflammatory and immunoregulatory activities. Pharmacological Action, Clinical Application and Adverse Reactions of Houttuynia Cordata. 46 (5), 395400. Chin. [20], In Australia, the Therapeutic Goods Administration has not given approval to Lianhua Qingwen, as it contains ephedra, a key ingredient used to make the drug methamphetamine. [5], Sources of its formulation reportedly consist of:[6], The medicine is both in capsule and granular form. Other related clinical studies also revealed that LHQW significantly improved the symptoms in COVID-19 patients and reduced the duration of fever, fatigue and cough and so forth, which provide preliminary research evidence for clinical treatment of COVID-19 [45,46]. LYY19H280006, No. sharing sensitive information, make sure youre on a federal Chin. Cui L.F., Xu H.R., Li F.Z., Wang C.X. A recent meta-analysis came from Zhang and Liu, (2014), focused on treatment for influenza A (H1N1) with LHQW in conjunction with oseltamivir. (2002). Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. Jiao Qu revised the manuscript. Med. In the evaluation of treating disease, the incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were lower in the LHQW group compared to the conventional drug group. Expert: Lianhua Qingwen capsule proven effective for COVID-19 - CGTN 37 (6), 25752579. 12 (08), 140141. Some composition of LHQW can cause damage to the stomach and intestines, supporting the possibility of injurious effects on the gastrointestinal system: for thia suspensa (Thunb.) [Fabaceae; Glycyrrhizae Radix et Rhizoma] (85g) (Rivera et al., 2014; Royal Botanic Gardens, Kew, 2021; Royal Botanic Gardens, Kew science, 2021; The Plant List, 2021; Yiling Pharmaceutical, 2021). [11] The pro-establishment DAB alliance was found to have distributed unregistered doses of LHQW, in breach of health regulations. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G.PRISMA Group (2009). There was no statistically significant difference in the incidence of adverse reactions during treatment of chronic obstructive pulmonary disease between the LHQW group and the conventional drug group (RR = 1.27, 95% CI = 0.513.17, p = 0.608). [Saururaceae; Houttuyniae Botanical drug], a composition of LHQW (Huang et al., 2021), that contains allergenic ingredients, such as chlorogenic acid, as well as the unstable nature of houttuyfonate, which can cause adverse reactions (Cao, 2016). Lianhua Qingwen Capsules of Yiling Pharmaceutical Approved in mauritius. Available at: http://m.news.cctv.com/2020/03/17/ARTIEYQ2aws8fPYWQxjnynzo200317.shtml?from=singlemessage (Accessed Apirl 29, 2021). Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Contraindications . H. Ohba [Crassulaceae; Rhodiolae Crenulatae Radix et Rhizoma] (85g), Mentha haplocalyx Briq. Methods: Comprehensive document retrieval was performed from both English and Chinese databases. For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). Chin. LHQW capsules also showed a multi-access effects on anti-human influenza A virus H3N2, including the prevention effect on virus adsorption, inhibition on virus proliferation after adsorption and direct killing of the virus [25]. Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. J. Pharmacovigilance. Here, we performed a meta-analysis of 217 Chinese experimental studies to evaluate the safety of LHQW. It argued that there was thus no reasonable basis for the mass distribution of the medication to healthy individuals to begin with, let alone doing so in a way that took up transportation capacity and resources that were urgently needed elsewhere. doi:10.5582/ddt.2020.03008, PubMed Abstract | CrossRef Full Text | Google Scholar, Cao, B., Zhang, D., and Wang, C. (2020). Clinical efficacy and mechanism of Lianhua Qingwen Granule on COVID-19 based on network pharmacology research. LHQW capsules not only had hemagglutination inhibition activity against B/Guangzhou/0215/2012 of influenza B virus, but also inhibited the over-expression of RANTES, IL-6, IL-8, IP-10, TNF-, MCP-1, macrophage inflammatory protein (MIP)-1, and interferon (IFN)- at the mRNA level and prevented a severe inflammatory response [26]. In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). Ping F., Li Z., Zhang F., Li D., Han S. Effects of Lianhua Qingwen on pulmonary oxidative lesions induced by fine particulates (PM2.5) in rats. Therefore, we conducted a systematic review of the . Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 20022003 in China. Received: 27 August 2021; Accepted: 06 January 2022;Published: 27 January 2022. (2020) identified 38 randomized controlled trials (RCTs) comparing LHQW with antivirals or other Chinese medicines for treating influenza and reported a lower risk of adverse reactions in the LHQW group compared to oseltamivir (RR = 0.29, 95%CI = 0.110.80), and ribavirin groups (RR = 0.29, 95%CI = 0.110.80). The duration of sputum was shorter in the Lianhua Qingwen group than in the conventional drug group (WMD = 1.10, 95% CI = 1.50 to 0.70, < 0.001). (2020). J. Nanjing Univ. Since the outbreak of COVID-19, Lianhua Qingwen Capsules have been recommended by the official Chinese "Diagnosis and Treatment Protocol for COVID-19" and widely used in designated admission hospitals for COVID-19. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. doi:10.1136/bmj.327.7414.557, Hu, C., Liang, M., Gong, F., He, B., Zhao, D., and Zhang, G. (2020). A systematic review on the efficacy of Traditional Chinese Medicine on influenza. The clinical application experience of LHQW has improved over the years, the clinical considers the patients condition, physical quality, and age, controls the amount of LHQW prescribed accordingly and thereby, reduced the likelihood of adverse reactions. There was no statistically significant difference in the incidence of adverse reactions during treatment of viral influenza between the LHQW group and the conventional drug group (RR = 0.75, 95% CI = 0.471.21, p = 0.244). Keywords: Covid-19: an Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Cheng D.Z., Li Y. (1990). Efficacy and safety of Lianhua Qingwen combined with - PubMed High-quality randomized controlled trials conducted over the long-term from multiple countries are warranted to further validate the efficacy and safety of LHQW. Therefore, further attention should be paid to the occurrence of adverse reaction with LHQW among different age groups in the future. Heterogeneity was evaluated using I2 statistic. doi:10.1056/NEJMc2008043, Cao, L. J. [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. We examined 54 studies on treatment of influenza, 42 of which reported adverse reactions. Careers, Unable to load your collection due to an error. The participants, interventions, comparison, outcome and study design (PICOS) criteria were used to identify articles: 1) participants: patients treated with LHQW, 2) interventions: LHQW or LHQW combined with conventional drug (LHQW capsule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20040063; LHQW granule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20100040), 3) comparison: conventional drugs, including antiviral drugs, conventional antibiotics or symptomatic treatment, 4) outcome: relevant data on adverse reactions, and 5) study design: experimental study.